Diversa Awarded $3.2M from NIH for Biodefense Antibody Optimization

Jul 25, 2003

NEW YORK, July 25 - Diversa, a San Diego-based microbial genomics firm, announced today that the National Institute of Allergy and Infectious Diseases was prepared to award the company approximately $3.2 million to optimize three antibodies that the U.S. army is already using for the detection of bioterrorism agents.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

Marks Left on the Genome

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

Cost and Coverage of Gene Therapies

The Wall Street Journal looks into the cost of new gene therapies.

Mosquito Population Crash

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

This Week in PNAS

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.

Main menu